Tyrosine kinase receptor (TRK) inhibitors targeting neurotrophic tyrosine receptor kinase (NTRK) gene fusions are the first “tumor agnostic” drugs approved for pan‐cancer use. This evidence concerns the gene NTRK1 and cancer.